Taipei, May 2025 — In response to the increasing demand for efficient development of antibody-drug conjugates (ADCs), ACROBiosystems has introduced a comprehensive ADC development solution platform, supporting every stage from target validation and drug-linker design to functional evaluation. This all-in-one product line is designed to accelerate discovery and improve the success rate of ADC drug development.

ACROBiosystems’ ADC solutions include:

• High-quality target proteins and cell lines: Active, validated targets for antibody screening and biomarker studies

• DAR quantification standards and analytical reagents: Well-characterized DAR (Drug-to-Antibody Ratio) standards to ensure data reliability

• Functional assay kits: Tools for internalization rate, cytotoxicity, binding affinity, and mechanism-of-action studies

• Linker-payload tools and labeled antibodies: To support structural characterization and optimization

These solutions help streamline ADC research workflows, reduce time-to-data, and enhance productivity across early discovery, preclinical evaluation, and process development phases.

In Taiwan, ACROBiosystems has appointed Genelabs Technologies Inc. as the exclusive distributor for its ADC product portfolio. Established in 1998, Genelabs is a trusted local partner known for its strong technical support, fast response time, and deep engagement in Taiwan’s biotechnology research community.

Contact Information
Genelabs Technologies Inc.
12F-6, No. 3, Yuanqu Street, Nangang District, Taipei City, Taiwan
Tel: +886-2-2655-7678
Email: genelabs@genelabs.com.tw
Website: https://www.genelabs.com.tw

Together, ACROBiosystems and Genelabs are committed to empowering Taiwan’s ADC developers with high-quality tools and localized service to accelerate the advancement of targeted cancer therapeutics.